1. Home
  2. MLYS vs LYTS Comparison

MLYS vs LYTS Comparison

Compare MLYS & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.92

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo LSI Industries Inc.

LYTS

LSI Industries Inc.

HOLD

Current Price

$18.53

Market Cap

703.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
LYTS
Founded
2019
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
703.3M
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
MLYS
LYTS
Price
$26.92
$18.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$48.67
$27.50
AVG Volume (30 Days)
1.3M
190.6K
Earning Date
05-11-2026
04-23-2026
Dividend Yield
N/A
1.08%
EPS Growth
37.43
N/A
EPS
N/A
0.43
Revenue
N/A
$573,377,000.00
Revenue This Year
N/A
$7.89
Revenue Next Year
N/A
$7.26
P/E Ratio
N/A
$43.05
Revenue Growth
N/A
22.09
52 Week Low
$10.44
$13.77
52 Week High
$47.65
$24.75

Technical Indicators

Market Signals
Indicator
MLYS
LYTS
Relative Strength Index (RSI) 53.31 37.82
Support Level $26.85 $17.97
Resistance Level $30.53 $19.41
Average True Range (ATR) 1.50 0.72
MACD 0.48 -0.03
Stochastic Oscillator 68.16 17.43

Price Performance

Historical Comparison
MLYS
LYTS

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.

Share on Social Networks: